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Abstract: Mass spectrometry plays a central role in structural proteomics, particularly in
highly intensive structural genomics projects. This review paper reports some examples taken
from recent work from the authors’ laboratory and is aimed at showing that modern pro-
teomics strategies are instrumental in the integration of structural genomic projects in fields
such as: (i) protein–protein interactions, (ii) protein–DNA interactions, (iii) protein–ligand
interactions, and (iv) protein-folding intermediates.
INTRODUCTION
Mass spectrometry (MS) is nowadays the core methodology in structural proteomics [1]. It plays a note-
worthy role in highly intensive projects aimed at giving a “form” to the monodimensional inputs of
genome sequencing (structural genomics). A number of strategies that combine protein chemistry pro-
cedures such as limited proteolysis, selective chemical modifications, and/or hydrogen/deuterium (H/D)
exchange with the unsurpassed sensitivity and dynamic range of analysis of MS, may actually provide
direct answers to different structural problems such as: (i) probing protein–protein interactions, (ii)
probing protein–DNA interactions, (iii) probing protein–ligand interactions, and (iv) probing protein-
folding intermediates.
Some examples aimed at showing that modern proteomics strategies are instrumental in the inte-
gration of structural genomic projects are outlined and discussed in this review paper.
PROBING PROTEIN–PROTEIN INTERACTIONS
A critical step toward the understanding of protein–protein interactions consists in the structural de-
scription of the contact regions within the complex. Focal points of the protein complex “form” may be
zoomed-out by the integration of protein chemistry and MS advanced tools. The mono-dimensional
data then can eventually be locked on a 3D template by the judicious use of molecular modeling and
dynamics. Structural proteomics actually combine the use of traditional protein chemistry tools (i.e.,
limited proteolysis and chemical reagents) duly revisited, with a modern MS armory. The revisitation
essentially consists in spotting only single chemical events occurring on the protein substrate. In order
to finely tune the specified reaction to this end, an array of experiments can be monitored by electro-
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spray (ES)-MS [2]. In contrast to the previous classical approach of protein chemistry, one can now
make use of both specific and aspecific reagents, and proteases can be used without taking into consid-
eration the total extent of the reaction [3].
As a result of “complementary” proteolysis experiments, the exact molecular mass of the two
complementary (poly)peptides, as determined by ES-MS often in trace amounts, immediately defines
the most exposed/flexible peptide bond in the selected conditions. By using the extensive armory of
available proteases, it is then possible to get a sufficiently detailed picture of the exposed protein back-
bone. Differential protein conformers can be highlighted when preferential proteolytic patterns of un-
bound protein structures and their complex(es) with molecular effector(s), either of low and high mo-
lecular weight, are compared using identical proteolytic conditions. As a corollary, cross-linking
reagents, in conditions to give a single molecular derivative, may be of paramount importance in pro-
viding structural constraint information, including orientation of secondary structure elements [4].
The topology of the Ca2+-calmodulin (CaM)-melittin ternary complex has been investigated by
the integrated strategy described above. Calcium-bound calmodulin is rapidly digested by proteases
with the most exposed regions being located within the second half of the long central helix connect-
ing the two domains in the native molecule. However, upon binding melittin, most of the cleavage sites
of calmodulin disappeared. Moreover, the central region of melittin was fully protected in the complex,
whereas the isolated peptide had been completely digested under the same conditions. The analysis of
the CaM-melittin complex using these integrated approaches showed that during the interaction,
calmodulin undergoes a dramatic conformational change in which the N- and C-terminal domains are
brought in close proximity by the disruption of the central helix, giving rise to a globular complex that
engulfs most of the melittin structure. Surprisingly, the ligand peptide was shown to interact with
calmodulin by adopting an opposite orientation within the complex (Fig. 1) as compared to all the pep-
tide substrate examined so far [4]. This finding adds a further dimension to the already remarkable ca-
pability of calmodulin in binding different protein substrates, thus suggesting that this protein might be
involved in regulating an even larger number of enzymatic activities.
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Fig. 1 3D structure of the CAM-mellittin complex showing the reverse orientation of the peptide (in magenta).
PROBING PROTEIN–DNA INTERACTIONS
The approach described above can also be applied to the investigation of protein–DNA binding. In pro-
tein–DNA complexes, in fact, the (poly)peptide regions responsible for DNA recognition, usually ac-
cessible in the isolated molecules, become protected following the interaction. 
Thyroid transcription factor 1 (TTF-1) is a 378-residue protein responsible for transcriptional ac-
tivation of genes expressed in follicular thyroid cells and lung epithelial cells. TTF-1 binds DNA by a
homeodomain (HD) of 61 amino acid residues, which specifically recognizes oligonucleotide se-
quences containing the 5′-CAAG-3′ core motif. The 3D structure of recombinant TTF-1HD has been
solved by NMR analysis, whereas no structural data are available for its complex with DNA. The topol-
ogy of the TTF-1HD/DNA complex was studied by integrating traditional protein chemistry tools with
MS methodologies [5]. When limited proteolysis digestions were carried out on the protein in the ab-
sence or presence of its target oligonucleotide, differential peptide maps were obtained from which the
amino acid residues involved in the interaction were inferred. Similarly, selective acetylation of lysine
residues in both the isolated and the complexed HD led to the identification of those amino acids
masked following DNA interaction. 
Surface topology analysis of isolated TTF-1HD performed at neutral pH was in good agreement
with the 3D structure of the molecule as determined by NMR studies in acidic conditions. Minor dif-
ferences were detected in the C-terminal region of the protein circled in Fig. 2, which, contrary to NMR
data, showed no accessibility to proteases. Analysis of the TTF-1HD/DNA complex provided an ex-
perimental validation of the model proposed for the interaction on the basis of the HD structures de-
scribed so far. An increased accessibility of the C-terminal region was observed following the interac-
tion, indicating that the C-terminal portion of HD is displaced from the protein surface by the
oligonucleotide molecule and adopts a disordered and flexible conformation. These findings suggest a
direct effect of DNA binding on the molecular conformation of the entire TTF-1 protein; the displace-
ment of the HD C-terminal tail might affect the C-terminal domain of the TTF-1 protein, causing this
region to assume a biologically relevant conformation. Comparative experiments with DNA fragments
differing for sequence and binding capability highlighted structural differences among the complexes,
mainly located in the N-terminal region of the HD, thus accounting for their different dissociation con-
stants. 
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Fig. 2 Structure of TTF-1HD. The circle indicates the C-terminal region of the protein.
PROBING PROTEIN–LIGAND INTERACTIONS
Two examples concerning either covalently and noncovalently bound effectors are described below,
showing how the proteomics strategies can integrate molecular modeling in the study of interactions of
ligands to proteins, leading eventually to the inactivation (phospholipase) or to the gain of function (lac-
toalbumin).
Petrosaspongiolide M (PM) is an anti-inflammatory marine metabolite that displays a potent in-
hibitory activity toward groups II and III secretory phospholipase A2 (PLA2) enzymes. The details of
the mechanism, which leads to a covalent adduct between PLA2 and hydroxybutenolide-containing
molecules such as PM, are still a matter of debate. The authors investigated the covalent binding of PM
to bee venom PLA2 by MS and molecular modeling [6]. The mass increment observed for the PM-
PLA2 adduct is consistent with the formation of a Schiff base by reaction of a PLA2 amino group with
the hemiacetal function at the C25 atom of the PM-hydroxybutenolide ring. Extensive proteolysis of
modified PLA2 by the endoprotease LysC followed by high-performance liquid chromatography MS
analysis allowed the authors to establish that the PLA2-amino terminal group residue was the single co-
valent binding site for PM. The stoichiometry of the reaction between PM and PLA2 was also moni-
tored, and results showed that even in the presence of excess inhibitor, the prevalent product is a 1:1 (in-
hibitor:enzyme) adduct, although a 2:1 adduct is present as a minor component. The 2:1 adduct was also
characterized, which showed that the second reaction site is located at the amino group of the Lys-85
residue. Similar results in terms of the reaction profile, mass increments, and location of the PLA2 bind-
ing site were obtained for manoalide, a paradigm for irreversible PLA2 inhibitors, which suggests that
the present results may be considered of general interest within the field of anti-inflammatory sestert-
erpenes that contain the hydroxybutenolide pharmacophore. Finally, a 3D model, constrained by the
above experimental results, was obtained by docking the inhibitor molecule into the PLA2 binding site
through AFFINITY calculations. The model provides an interesting insight into the PM-PLA2 inhibi-
tion process and may prove useful in the design of new anti-inflammatory agents that target PLA2 se-
cretory enzymes.
A combination of H/D exchange and limited proteolysis experiments coupled to MS analysis was
used to depict the conformation of a folding variant of α-lactalbumin, endowed with the peculiar bio-
logical function of inducing apoptosis in tumor and immature cells. This conformer named HAMLET
(human α-lactalbumin made lethal to tumor cells) and stabilized by the interaction with a specific fatty
acid, C18:1 [7]. Human α-lactalbumin (holo) is a 14 kDa protein whose structure is made of two do-
mains containing a single tightly bound Ca2+ and four disulfide bonds, and at least two different con-
formations of α-lactalbumin have already been described under different physicochemical conditions,
i.e., at low pH (A state) and in the absence of Ca2+ (apo). Nevertheless, structural details of HAMLET
accounting for its molecular diversity from other forms of α-lactalbumin are lacking, so far. Near and
far UV CD, fluorescence, and 8-anilino-1-naphthalenesulfonate (ANS) binding were not able to dis-
criminate between HAMLET and apo-α-lactalbumin, because they exhibit very similar spectroscopic
characteristics [8,9].
H/D exchange experiments clearly indicated that HAMLET and apo are indeed two different con-
formers of α-LA, both differing from holo-α-lactalbumin. By extending the above concepts, D2O can
be viewed as an aspecific chemical reagent in establishing, either globally or locally, the exposition of
peptide backbones. HAMLET incorporated a greater number of deuterium atoms compared to the apo
and holo forms. Moreover, the apo α-lactalbumin appeared to be a mixture of at least two populations
of conformers with different exchange properties.
“Complementary” proteolysis experiments showed that HAMLET and apo are both accessible to
proteases in the β-domain with cleavages occurring at the same sites as illustrated on the three-dimen-
sional structure of holo-α-lactalbumin in Fig. 3. Nevertheless, substantial differences in the kinetics of
enzymatic digestion at specific sites were observed. In particular, Asp37, Tyr50, and Phe53 were found
to be by far more exposed in HAMLET than in apo. These results were supported by the analysis of the
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peptides generated from the peptic digest of deuterium-exchanged α-lactalbumin conformers, and sug-
gested that binding of oleic acid might displace the central strand of the β-sheet, exposing Asp37,
Tyr50, and Phe53 (Fig. 3). 
Low-resolution approaches such us limited proteolysis and H/D exchange experiments in con-
junction with MS analysis were shown, therefore, to be instrumental in providing subtle structural de-
tails on highly flexible conformations such as HAMLET or apo. Modern views in structural proteomics
have already recognized that the flexibility of proteins is instrumental not only to exploit catalytic ac-
tivity but also to alter their biological functions, conferring peculiar properties to different conforma-
tions of the molecule. Thereof, proteomic studies which require information of the structural changes
associated with different biological functions of the same (poly)peptide chain, will more and more rely
on the kind of approaches described in this section.
PROBING PROTEIN-FOLDING INTERMEDIATES
In protein-folding studies, MS can be used to characterize the population of species formed on the fold-
ing pathway, and the disulfide bonds present at different times of the process. Aliquots of the reaction
mixture withdrawn at different times during the oxidative folding process are trapped by alkylation of
the free thiol and analyzed by ES-MS. The alkylation reaction prevents reoxidation and increases the
molecular mass of the intermediates by a fixed amount for each reacted free SH group. Intermediates
containing different numbers of disulfide bonds are separated by mass, and their relative abundance in
the sample is determined. The nature + quantitative distribution of the disulfide-bonded species present
at a given time can be used to establish the refolding pathway of the protein and, in some cases, to de-
velop a kinetic analysis of the process. 
Once the refolding intermediates have been characterized by ES-MS in terms of their content of
disulfide bonds, a further step would consist in the structural assignment of the various disulfide bonds
formed at different times in the entire process by peptide mapping using matrix-assisted laser desorp-
tion ionization MS (MALDI-MS). The refolding intermediates are cleaved at points between the po-
tentially bonded cysteine residues under conditions known to minimize disulfide reduction and reshuf-
fling in attempts to isolate any cysteine residue within an individual peptide. The MALDI-MS mapping
approach is then used to search for any S–S bonded peptides, which are characterized by their unique
masses. The interpretation is then confirmed by performing reduction or Edman degradation steps fol-
lowed by rerunning the MS spectrum [10].
Snake neurotoxins are short all-β proteins that display a complex organization of the disulfide
bonds: two bonds connect consecutive cysteine residues (C43–C54, C55–C60), and two bonds intersect
when bridging (C3–C24, C17–C41) to form a particular structure classified as “disulfide ß-cross” [11]
© 2003 IUPAC, Pure and Applied Chemistry 75, 309–316
Proteomics strategies in protein structure–function studies 313
Fig. 3 Preferential cleavage sites observed in HAMLET and apo α-LA mapped on the 3D structure of holo α-LA.
shown in Fig. 4. The general organization of the (poly)peptide chain in snake toxins generates a trefoil
structure termed “three-fingers fold”. The authors showed [12] that a single mutation located in turn 2
substantially alters the rate of the sequential folding process of the protein. The authors used three vari-
ants for which the length of this turn was increased from three (variant α60) to four (toxin α) and then
to five (variant α62) residues. The increase in the length of the turn slowed down the folding process so
that after 2 h of incubation, about 90 % of the variant α60 was folded, whereas this value decreased to
about 70 % for the 61 residues toxin α and 20 % for the variant α62. Interestingly, three disulfide-con-
taining intermediates were the predominant species for all variants folding, but this population was
markedly more abundant and persistent for the slowest-folding neurotoxin. 
Two intermediates containing three disulfides were found to accumulate during early and late
stages of neurotoxin α62 folding [13]. Both intermediates consisted of chemically homogenous species
containing three of the four native disulfide bonds and lacking the C43–C54 and the C17–C41 coupling,
respectively. A model of the folding pathway of neurotoxin α62 was proposed by the authors and is il-
lustrated in Fig. 5. The des-[43–54] intermediate appeared to be the immediate precursor of the native
species. Conversely, the des-[17–41] species was unable to form the fourth disulfide bond and had to
rearrange into intermediates that can directly reach the native state. These isomerization reactions pro-
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Fig. 4 Ribbon structure of snake neurotoxins. Sequence alignment of variants used in this study. The sequence of
turn 2 is underlined.
Fig. 5 Model of the folding pathway of neurotoxin α62.
vide an explanation for the accumulation of three disulfide intermediates along the pathway, which
caused the slow oxidative folding, observed for neurotoxin α62. 
Integration of spectroscopic investigations and MS procedures might be instrumental in provid-
ing subtle structural details on transient conformations such as those present along a folding pathway
even in the absence of disulfide bonds, as demonstrated by the characterization of a partly folded inter-
mediate of aspartate aminotransferase from Escherichia coli [14]. In conjunction with spectroscopic
techniques, H/D exchange and limited proteolysis experiments coupled to MS analysis were used to de-
pict the topology of the monomeric M* partly folded intermediate in wild-type (WT) as well as in a mu-
tant form of aspartate aminotransferase from E. coli (EcAspAT) in which the highly conserved cis-pro-
line at position 138 was replaced by a trans-alanine (P138A) [15]. Fluorescence analysis indicated that
while M* is an off-pathway intermediate in the folding of WT EcAspAT, it seems to coincide with an
on-pathway folding intermediate for the P138A mutant. Gel filtration and CD analysis did not show
major differences between the two M* species. On the contrary, the increased deuterium incorporation
level and the higher accessibility to proteases shown by WT-M* as compared to P138A-M*, demon-
strated the occurrence of conformational differences between the M* intermediates. These results, to-
gether with fluorescence data, indicate that P138A-M* is conceivably more compact than WT-M*.
Limited proteolysis data, summarized in Fig. 6, suggested that the conformational differences might be
related to a different relative orientation of the small and large domains of the protein induced by the
presence of the cis-proline residue at position 138 in the WT protein. The relative rotation of the two
domains might also affect the conformation of the N-terminal tail, thus explaining the accessibility of
the segment 20–25, located in the small domain close to the N-terminus of the protein. The differences
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Fig. 6 Preferential proteolytic sites mapped onto the amino acid sequence of EcAspAT. Cleavage sites only
occurring in WT-M* are indicated by green arrows, those only present in P138A-M* by red arrows and those
observed in both proteins by black arrows. Regions underlined in red, pale blue, and green indicate the N-terminal
tail, the large domain and the small domain, respectively. Residues occurring at the domain interface are
highlighted in pale blue, and those at the subunit interface are highlighted in yellow. 
between the two M* species suggest that in WT-M* Pro138 is in the cis conformation at this stage of
the folding process. 
CONCLUSIONS
Large structural genomic projects face several different bottlenecks owing to the innate methodological
requirements by X-ray diffraction and NMR studies (for a recent review, see [16]). Modern proteomic
strategies, as outlined above, may be instrumental in high-throughput structure determination studies
both at the top and the bottom of the conveyor belt of structural genomics in providing: (a) protein qual-
ity control; (b) folding optimization; (c) models validation; (d) structural constraints; and in probing: (i)
functioning structures; (ii) ligand interactions; and (iii) metastable states.
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